Abstract：
BACKGROUND: We report the case of a woman with drusenoid pigment epithelial detachment (DPED) in age-related macular degeneration who was successfully treated with two monthly intravitreal injections of brolucizumab after failing to respond to previous intravitreal injections of bevacizumab and aflibercept.
METHODS: A 56-year-old woman with mixed DPED and overlying subretinal fluid in her right eye was initially treated with three intravitreal injections of bevacizumab and three intravitreal injections of aflibercept with no visual and anatomical improvement. Switching to intravitreal injection of brolucizumab was performed. After two consecutive monthly intravitreal injections of brolucizumab, optical coherence tomography (OCT) showed first subretinal fluid resolution and then DPED collapse in the following months. After nine months, the best corrected visual acuity had improved from 20/40 to 20/20. There were no signs of retinal atrophy and exudative activity on OCT examination. No serious or minor adverse events were reported during the follow-up period.
CONCLUSIONS: Switching to intravitreal brolucizumab injection might be an effective therapeutic option for treatment of mixed DPED with subretinal fluid refractory to other anti-VEGF drugs.
METHODS: A 56-year-old woman with mixed DPED and overlying subretinal fluid in her right eye was initially treated with three intravitreal injections of bevacizumab and three intravitreal injections of aflibercept with no visual and anatomical improvement. Switching to intravitreal injection of brolucizumab was performed. After two consecutive monthly intravitreal injections of brolucizumab, optical coherence tomography (OCT) showed first subretinal fluid resolution and then DPED collapse in the following months. After nine months, the best corrected visual acuity had improved from 20/40 to 20/20. There were no signs of retinal atrophy and exudative activity on OCT examination. No serious or minor adverse events were reported during the follow-up period.
CONCLUSIONS: Switching to intravitreal brolucizumab injection might be an effective therapeutic option for treatment of mixed DPED with subretinal fluid refractory to other anti-VEGF drugs.
摘要：
背景：我们报告了一例年龄相关性黄斑变性患者的色斑样色素上皮脱离（DPED），该患者在对先前的玻璃体内注射贝伐单抗和阿柏西普无效后，每月两次玻璃体内注射brolucizumab成功治疗。
方法：一名56岁女性，其右眼患有混合DPED和视网膜下液，最初接受了三次玻璃体内注射贝伐单抗和三次玻璃体内注射阿柏西普治疗，但视觉和解剖学上没有改善。切换到玻璃体内注射brolucizumab。在连续两个月的玻璃体内注射Brolucizumab后，光学相干断层扫描(OCT)在接下来的几个月中首先显示视网膜下液分辨率,然后显示DPED塌陷.九个月后,最佳矫正视力从20/40提高到20/20。在OCT检查中没有视网膜萎缩和渗出活动的迹象。随访期间未报告严重或轻微的不良事件。
结论：转用玻璃体内注射布卢珠单抗可能是治疗其他抗VEGF药物难以治疗的混合DPED和视网膜下液的有效治疗选择。
方法：一名56岁女性，其右眼患有混合DPED和视网膜下液，最初接受了三次玻璃体内注射贝伐单抗和三次玻璃体内注射阿柏西普治疗，但视觉和解剖学上没有改善。切换到玻璃体内注射brolucizumab。在连续两个月的玻璃体内注射Brolucizumab后，光学相干断层扫描(OCT)在接下来的几个月中首先显示视网膜下液分辨率,然后显示DPED塌陷.九个月后,最佳矫正视力从20/40提高到20/20。在OCT检查中没有视网膜萎缩和渗出活动的迹象。随访期间未报告严重或轻微的不良事件。
结论：转用玻璃体内注射布卢珠单抗可能是治疗其他抗VEGF药物难以治疗的混合DPED和视网膜下液的有效治疗选择。
